N. PARVEEN, V. KHARE, F. HAIDER, S. KHAN, S.S. CHAUHAN, S. ALI AND S.K. VISHWAKARMA
Abstract
One of the most common health issues affecting women is bacterial vaginosis (BV), that is result from alterations in the vaginal microbiome. It is frequently linked to vaginal inflammation, affects womenâs reproductive health and an increased chance of contracting sexually transmitted infections (STIs) such as HIV. Preterm premature rupture of the membranes and preterm birth are among the negative pregnancy outcomes that can result from BV in pregnant women, along with chorioamnionitis. Numerous risk variables, including age, sexual behavior, socioeconomic level, use of antibiotics, and ethnicity contributes to its pathophysiology. Due to the complicated polymicrobial nature of BV, diagnosis has proven difficult; nevertheless, there are numerous tests that may be used to determine the infection, including the gold standard now in use, which is the standardized evaluation of morphotypes on Gram stain analysis, as well as real-time clinical and microbiological testing. Conventional clinical and microscopic approaches have lower sensitivity and specificity, need more personnel and time, and are less accurate. Vaginal culture used improperly can be deceptive. Novel diagnostic techniques, such as point-of-care (POC) tests with high sensitivity and specificity. Inaccurate diagnosis of BV increases the risk of negative consequences for womenâs reproductive health and delayed treatment. Antigen-based diagnostics are expected to provide better insights into the disruption of vaginal flora caused by BV. Research highlights the global epidemiology of BV, risk factors, sexual transmission of BV-associated bacteria, and the potential of molecular diagnostic tests to improve detection and management.